Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roblin

Showing results (631-640 of 756) with videos related to

Pageof 76
Sort By:
American Journal of Obstetrics and Gynecology|September 3, 2004
Prescription drug use in pregnancySusan E Andrade, Jerry H Gurwitz, Robert L Davis, et al.
JAMA|June 14, 2012
Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996-2010Rebecca Smith-Bindman, Diana L Miglioretti, Eric Johnson, et al.
Pharmacoepidemiology and Drug Safety|April 6, 2006
Use of prescription medications with a potential for fetal harm among pregnant womenSusan E Andrade, Marsha A Raebel, Abraham N Morse, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 25, 2024
Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER StudyGuillaume Bouguen, Laure Gossec, Vered Abitbol, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 14, 2013
Involvement of protein IF2 N domain in ribosomal subunit joining revealed from architecture and function of the full-length initiation factorAngelita Simonetti, Stefano Marzi, Isabelle M L Billas, et al.
Psycho-Oncology|June 20, 2013
Patients' and family members' views on patient-centered communication during cancer careKathleen M Mazor, Reneé L Beard, Gwen L Alexander, et al.
BMC Gastroenterology|June 8, 2022
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysisLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Medical Care|July 2, 2014
Effect of self-referral on bone mineral density testing and osteoporosis treatmentAmy H Warriner, Ryan C Outman, Adrianne C Feldstein, et al.
Alimentary Pharmacology & Therapeutics|April 27, 2022
Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE StudyNiels Vande Casteele, William J Sandborn, Brian G Feagan, et al.
Pharmacoepidemiology and Drug Safety|January 23, 2002
Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on TherapeuticsR Platt, R Davis, J Finkelstein, et al.
Pageof 76

Showing results (631-640 of 756) with videos related to

Sort By:
Pageof 76
American Journal of Obstetrics and Gynecology|September 3, 2004
Prescription drug use in pregnancySusan E Andrade, Jerry H Gurwitz, Robert L Davis, et al.
JAMA|June 14, 2012
Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996-2010Rebecca Smith-Bindman, Diana L Miglioretti, Eric Johnson, et al.
Pharmacoepidemiology and Drug Safety|April 6, 2006
Use of prescription medications with a potential for fetal harm among pregnant womenSusan E Andrade, Marsha A Raebel, Abraham N Morse, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 25, 2024
Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER StudyGuillaume Bouguen, Laure Gossec, Vered Abitbol, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 14, 2013
Involvement of protein IF2 N domain in ribosomal subunit joining revealed from architecture and function of the full-length initiation factorAngelita Simonetti, Stefano Marzi, Isabelle M L Billas, et al.
Psycho-Oncology|June 20, 2013
Patients' and family members' views on patient-centered communication during cancer careKathleen M Mazor, Reneé L Beard, Gwen L Alexander, et al.
BMC Gastroenterology|June 8, 2022
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysisLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Medical Care|July 2, 2014
Effect of self-referral on bone mineral density testing and osteoporosis treatmentAmy H Warriner, Ryan C Outman, Adrianne C Feldstein, et al.
Alimentary Pharmacology & Therapeutics|April 27, 2022
Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE StudyNiels Vande Casteele, William J Sandborn, Brian G Feagan, et al.
Pharmacoepidemiology and Drug Safety|January 23, 2002
Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on TherapeuticsR Platt, R Davis, J Finkelstein, et al.
Pageof 76